Tavapadon for Parkinson's Disease (TEMPO-4 Trial)

"Research for Tavapadon began in 2019 with a clinical trial sponsored by Cerevel Therapeutics, LLC. A second study was conducted that same year which resulted in Tavapadon's approval as a Phase 3 drug. Currently, there are 4 active studies being conducted in 85 cities and 14 countries."

"Unfortunately, this particular trial is no longer recruiting patients. It was originally posted on February 24th, 2021 and had its last update September 7th, 2022. If you are still seeking trials to participate in, there are 515 other studies for Parkinson's disease and 4 for Tavapadon currently looking for participants."

"This clinical trial is open to 531 people with parkinson disease, aged 40-80. In order to be eligible, patients must meet the following criteria: They must have completed a previous 27 week double-blind treatment period from one of three trials, and enter this trial within 72 hours of their last visit from that study. Additionally, participants must agree to use birth control throughout the duration of the trial if they are sexually active, and refrain from taking any medication not permitted by the protocol. Lastly, investigators must judge the participant as being compliant with IMP requirements and willing to follow all restrictions laid out in the ICF and protocol."

"Eligibility requirements for this study show that patients must be between 40-80 years old. In contrast, there are 29 trials specifically for children and 516 studies searching for elderly participants."

"Tavapadon was first studied in 2019 at Springub. Since then, there have been a total of six completed studies. There are four active clinical trials underway as of now; many of these are being conducted in Phoenix, Arizona."

"Tavapadon's safety is estimated to be a 3 by our team at Power. This is due to the fact that Tavapadon is currently in Phase 3 clinical trials, meaning there have been multiple rounds of data supporting its efficacy and safety."